Clinical Trials Directory

Trials / Completed

CompletedNCT05249803

"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19

"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19 Pneumonia Admitted in Intensive Care Unit of a Tertiary Care Hospital in Lahore, Pakistan": A Retrospective Cohort Study

Status
Completed
Phase
Study type
Observational
Enrollment
133 (actual)
Sponsor
FMH College of Medicine and Dentistry · Academic / Other
Sex
All
Age
16 Years – 85 Years
Healthy volunteers
Not accepted

Summary

COVID-19, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is a multisystem disease which primarily involves the respiratory tract. The first case of COVID-19 was identified in late 2019 in the province of Wuhan, China which was followed by the rapid spread of the disease globally, becoming a present-day pandemic. Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore.

Detailed description

Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore. Material \& Methods: Study design: Retrospective study. Study Settings: Study was conducted in Fatima Memorial Hospital, Lahore. Study Duration: Study was conducted on Covid-19 patients who were admitted from March 2021 to August 2021.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTPatients with COVID-19 PneumoniaPatients were offered with usual care of COVID-19 in ICU and we did retrospective study

Timeline

Start date
2021-03-01
Primary completion
2021-08-31
Completion
2021-12-31
First posted
2022-02-22
Last updated
2022-02-22

Locations

1 site across 1 country: Pakistan

Regulatory

Source: ClinicalTrials.gov record NCT05249803. Inclusion in this directory is not an endorsement.